Method of administering liposomal encapsulated taxane

Abstract

Liposomal-encapsulated taxane or an antineoplastic derivative thereof or a mixture thereof is provided which is used to effect a therapeutically enhanced method of treating cancer. The liposomal encapsulated paclitaxel allows for administration to a patient, particularly a human patient, in less than one hour without substantial toxicity.

1 . A method of administering a taxane comprising administering to a human patient a pharmaceutical composition, over a period of less than an hour, comprising up to about 300 mg/m 2  of taxane wherein said pharmaceutical composition further comprises liposomes.  
   
   
       2 . The method of  claim 1 , wherein said taxane is selected from the group consisting of paclitaxel, 7-epipaclitaxel, t-acetyl paclitaxel, 10-desacetyl-paclitaxel, 10-desacetyl-7-epipaclitaxel, 7-xylosylpaclitaxel, 10-desacetyl-7-glutarylpaclitaxel, 7-N,N-dimethylglycylpaclitaxel, 7-L-alanylpaclitaxel, taxotere, and mixtures thereof.  
   
   
       3 . The method of  claim 1 , wherein the taxane is paclitaxel.  
   
   
       4 . The method of  claim 1 , wherein at least one liposome contains cardiolipin.  
   
   
       5 . The method of  claim 4 , wherein the cardiolipin is synthetic cardiolipin.  
   
   
       6 . The method of  claim 4 , wherein the cardiolipin is tetramyristoyl cardiolipin.  
   
   
       7 . The method of  claim 1 , wherein the liposome further comprises a-tocopherol.  
   
   
       8 . The method of  claim 1 , wherein the liposome further comprises cholesterol.  
   
   
       9 . The method of  claim 1 , wherein the amount of taxane is at least about 75 mg/m 2 .  
   
   
       10 . The method of  claim 1 , wherein the amount of taxane is up to about 75 mg/m 2 .  
   
   
       11 . The method of  claim 1 , wherein the amount of taxane is at least about 135 mg/m 2 .  
   
   
       12 . The method of  claim 1 , wherein the amount of taxane is up to about 135 mg/m 2 .  
   
   
       13 . The method of  claim 1 , wherein the amount of taxane is at least about 175 mg/m 2 .  
   
   
       14 . The method of  claim 1 , wherein the amount of taxane is up to about 175 mg/m 2 .  
   
   
       15 . The method of  claim 1 , wherein the amount of taxane is at least about 250 mg/m 2 .  
   
   
       16 . The method of  claim 1 , wherein the amount of taxane is up to about 250 mg/m 2 .  
   
   
       17 . The method of  claim 1 , wherein the amount of taxane is about 300 mg/m 2 .  
   
   
       18 . The method of  claim 1 , wherein the taxane is administered by intravenous infusion.  
   
   
       19 . The method of  claim 18 , wherein the taxane is administered over a period of about 45 minutes.  
   
   
       20 . The method of  claim 1 , wherein the taxane is administered continuously over said period.  
   
   
       21 . The method of  claim 1 , wherein the administration of taxane is repeated at least once every 21 days.  
   
   
       22 . The method of  claim 1 , wherein the taxane is administered to the peritoneum of a patient suffering from cancer.  
   
   
       23 . The method of  claim 1 , wherein the taxane is administered to a patient patients suffering from colon cancer.  
   
   
       24 . The method of  claim 1 , wherein the taxane is administered to a patient suffering from prostate cancer.  
   
   
       25 . The method of  claim 1 , wherein the taxane is administered to a patient suffering from head and neck cancer.  
   
   
       26 . The method of  claim 1 , wherein the taxane is administered to a patient suffering from ovarian cancer, breast cancer, or lung cancer.